Applying machine learning to detect early stages of cardiac remodelling and dysfunction. (26th June 2020)

• Record Type: Journal Article
• Authors: Sabovčik, František; Cauwenberghs, Nicholas; Kouznetsov, Dmitry; Haddad, Francois; Alonso-Betanzos, Amparo; Vens, Celine; Kuznetsova, Tatiana
• Is Part Of: European heart journal. Volume 22:Number 10(2021)
• Page Start: 1208
• Page End: 1217
• Publication Date: 2020-06-26
• Subjects: echocardiography -- machine learning -- diastolic dysfunction -- left ventricular hypertrophy; Cardiovascular system -- Imaging -- Periodicals; Heart -- Imaging -- Periodicals; 616.10754
• DOI: 10.1093/ehjci/jeaa135
• Languages: English
• ISSNs: 2047-2404

Abstract

Abstract: Aims: Both left ventricular (LV) diastolic dysfunction (LVDD) and hypertrophy (LVH) as assessed by echocardiography are independent prognostic markers of future cardiovascular events in the community. However, selective screening strategies to identify individuals at risk who would benefit most from cardiac phenotyping are lacking. We, therefore, assessed the utility of several machine learning (ML) classifiers built on routinely measured clinical, biochemical, and electrocardiographic features for detecting subclinical LV abnormalities. Methods and results: We included 1407 participants (mean age, 51 years, 51% women) randomly recruited from the general population. We used echocardiographic parameters reflecting LV diastolic function and structure to define LV abnormalities (LVDD, n = 252; LVH, n = 272). Next, four supervised ML algorithms (XGBoost, AdaBoost, Random Forest (RF), Support Vector Machines, and Logistic regression) were used to build classifiers based on clinical data (67 features) to categorize LVDD and LVH. We applied a nested 10-fold cross-validation set-up. XGBoost and RF classifiers exhibited a high area under the receiver operating characteristic curve with values between 86.2% and 88.1% for predicting LVDD and between 77.7% and 78.5% for predicting LVH. Age, body mass index, different components of blood pressure, history of hypertension, antihypertensive treatment, and various electrocardiographic variables were the top selected features for predicting LVDD and LVH. Conclusion: XGBoost and RF classifiers combining routinely measured clinical, laboratory, and electrocardiographic data predicted LVDD and LVH with high accuracy. These ML classifiers might be useful to pre-select individuals in whom further echocardiographic examination, monitoring, and preventive measures are warranted.